Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
- Aug 05, 2022 (filed on Aug 09, 2022)Insider Name:Invus US Partners LLCOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:147,390Price:$2.50
- Aug 05, 2022 (filed on Aug 09, 2022)Insider Name:Artal International S.C.A.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:2,426,070Price:$2.50
- Aug 01, 2022 (filed on Aug 01, 2022)Insider Name:Debbane RaymondOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:982,600Price:$2.50
- Aug 01, 2022 (filed on Aug 01, 2022)Insider Name:Invus US Partners LLCOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:982,600Price:$2.50
- Aug 01, 2022 (filed on Aug 01, 2022)Insider Name:Artal International S.C.A.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:16,173,800Price:$2.50
- May 21, 2022 (filed on May 23, 2022)Insider Name:Swain Judith LOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:9,302Price:--
- May 21, 2022 (filed on May 23, 2022)Insider Name:Swain Judith LOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:14,402Price:--
- May 21, 2022 (filed on May 23, 2022)Insider Name:Sobecki Christopher JOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:9,302Price:--
- May 21, 2022 (filed on May 23, 2022)Insider Name:Sobecki Christopher JOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:14,402Price:--
- May 21, 2022 (filed on May 23, 2022)Insider Name:Nies Alan SOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:9,302Price:--
Filings by filing date
- Aug 05, 2022 (filed on Aug 09, 2022)Insider Name:Invus US Partners LLCOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:147,390Price:$2.50
- Aug 05, 2022 (filed on Aug 09, 2022)Insider Name:Artal International S.C.A.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:2,426,070Price:$2.50
- Aug 01, 2022 (filed on Aug 01, 2022)Insider Name:Debbane RaymondOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:982,600Price:$2.50
- Aug 01, 2022 (filed on Aug 01, 2022)Insider Name:Invus US Partners LLCOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:982,600Price:$2.50
- Aug 01, 2022 (filed on Aug 01, 2022)Insider Name:Artal International S.C.A.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:16,173,800Price:$2.50
- May 21, 2022 (filed on May 23, 2022)Insider Name:Swain Judith LOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:9,302Price:--
- May 21, 2022 (filed on May 23, 2022)Insider Name:Swain Judith LOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:14,402Price:--
- May 21, 2022 (filed on May 23, 2022)Insider Name:Sobecki Christopher JOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:9,302Price:--
- May 21, 2022 (filed on May 23, 2022)Insider Name:Sobecki Christopher JOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:14,402Price:--
- May 21, 2022 (filed on May 23, 2022)Insider Name:Nies Alan SOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:9,302Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 8800 TECHNOLOGY FOREST PLACE 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381 |
Tel: | N/A |
Website: | https://www.lexpharma.com |
IR: | See website |
Key People | ||
Jeffrey L. Wade President, Chief Financial Officer | Lonnel Coats Chief Executive Officer, Director | Alan J. Main Executive Vice President - Innovation and Chemical Sciences |
Brian T. Crum Senior Vice President, General Counsel | Craig B. Granowitz Senior Vice President, Chief Medical Officer | Kenneth B. Kassler-Taub Senior Vice President - Regulatory and Quality Assurance |
Kristen L. Alexander Vice President - Finance and Accounting | Wendy E. Mcdermott Vice President - Human Resources | Kiernan A. Seth Vice President, Chief Commercial Officer |
Business Overview |
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its pipeline includes Sotagliflozin, LX9211, and LX2761. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes, heart failure and chronic kidney disease. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney. |
Financial Overview |
For the six months ended 30 June 2022, Lexicon Pharmaceuticals, Inc. revenues decreased 72% to $72K. Net loss increased 23% to $48.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development -other increase of 28% to $26.2M (expense), General and administrative - other increase of 21% to $15.7M (expense). |
Employees: | 87 as of Feb 28, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $530.90M as of Jun 30, 2022 |
Annual revenue (TTM): | $0.11M as of Jun 30, 2022 |
EBITDA (TTM): | -$95.25M as of Jun 30, 2022 |
Net annual income (TTM): | -$96.80M as of Jun 30, 2022 |
Free cash flow (TTM): | -$88.13M as of Jun 30, 2022 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 183,625,743 as of Aug 3, 2022 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |